CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
Prior systemic treatment for the disease under study
Prior surgery
Prior radiation therapy to the abdomen or pelvis
Current recipient or receipt within 5-half-lives of C1D1 of any of the following: chemotherapy, biologic/targeted therapy, herbal medications or supplements, immunomodulator therapy for any disease indication.
History of noninfectious pneumonitis/interstitial lung disease (ILD) within 6 months of first dose of study drug.
Active, progressive, or symptomatic brain metastases
Participants considered poor medical risks due to serious, uncontrolled medical conditions, active infections, or nonmalignant systemic diseases
Pregnant or breastfeeding women
Clareo Health | CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
